Sothema: Increase in consolidated turnover in the 1st quarter

Sothema: Increase in consolidated turnover in the 1st quarter
Sothema: Increase in consolidated turnover in the 1st quarter

By The Economist | 05/27/2024 – 2:07 p.m. | Share

Sothema recorded an increase in its consolidated turnover in the first quarter. The latter stood at 656 million DH compared to 597 million DH a year earlier, representing growth of 10% year-on-year. This development was supported by the commercial dynamics of Sothema and its subsidiaries, notably Axess Pharma in Morocco and West Afric Pharma in Senegal. At the end of last March, the company also invested 83 million DH compared to 13 million DH at the same period in 2023.

The investments concerned various projects intended to increase its industrial and technological capacities. As for the consolidated net debt, it reached 506 million DH at the end of the first quarter of 2024 compared to 448 million DH at the end of December 2023, an increase of 58 million DH.

Furthermore, Sothema continues to enrich its product portfolio in accordance with its policy of improving its Time To Market. At the end of March 2024, the company launched two new high value-added products on the market. For the remainder of this financial year, the company should obtain nine new Marketing Authorizations (AMM) in Morocco and 10 internationally.

-

-

PREV Incidents at Boeing: the boss recognizes a “manufacturing defect” and admits the “seriousness” of the situation
NEXT Bitcoin, future international reserve currency?